Published in Am J Pediatr Hematol Oncol on January 01, 1982
Simvastatin (Zocor) Therapy in Sickle Cell Disease | NCT00508027
Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest (2000) 5.88
Circulating activated endothelial cells in sickle cell anemia. N Engl J Med (1997) 5.13
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest (2000) 2.47
Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest (1980) 2.34
The relative magnitudes of endothelial force generation and matrix stiffness modulate capillary morphogenesis in vitro. Exp Cell Res (2004) 2.25
Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med (1980) 2.14
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 2.10
Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest (1982) 1.93
VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res (1999) 1.91
Reperfusion injury pathophysiology in sickle transgenic mice. Blood (2000) 1.65
Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol (2001) 1.61
Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol (2000) 1.60
CD36-positive stress reticulocytosis in sickle cell anemia. J Lab Clin Med (1996) 1.59
Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest (1998) 1.58
The adhesive sickle erythrocyte: cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes. Clin Haematol (1985) 1.51
alpha-Ketoacids scavenge H2O2 in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. Am J Physiol (1995) 1.38
Intracellular targets in heme protein-induced renal injury. Kidney Int (1998) 1.33
Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis (1999) 1.31
Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood (1992) 1.24
Phagocytosis of sickle erythrocytes: immunologic and oxidative determinants of hemolytic anemia. Blood (1984) 1.23
Influence of treatment and response status on infection risk in multiple myeloma. Am J Med (1981) 1.21
Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood (2001) 1.17
Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol (1985) 1.16
Clinical diversity of sickle cell anemia: genetic and cellular modulation of disease severity. Am J Hematol (1983) 1.14
Abnormal redox status of membrane-protein thiols in sickle erythrocytes. J Clin Invest (1985) 1.14
Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood (1991) 1.14
Blood cell abnormalities complicating the hypophosphatemia of hyperalimentation: erythrocyte and platelet ATP deficiency associated with hemolytic anemia and bleeding in hyperalimented dogs. J Lab Clin Med (1974) 1.12
Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. J Clin Invest (1993) 1.11
Differential endothelial cell gene expression by African Americans versus Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer. BMC Med (2011) 1.11
Human llamas: adaptation to altitude in subjects with high hemoglobin oxygen affinity. J Clin Invest (1978) 1.08
A novel technique for culture of human dermal microvascular endothelial cells under either serum-free or serum-supplemented conditions: isolation by panning and stimulation with vascular endothelial growth factor. Exp Cell Res (1997) 1.07
Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol (1996) 1.03
Nucleosomal histone protein protects DNA from iron-mediated damage. Nucleic Acids Res (1992) 1.03
Synergistic effects of oxidation and deformation on erythrocyte monovalent cation leak. Blood (1990) 1.00
Internucleosomal cleavage of DNA as the sole criterion for apoptosis may be artifactual. J Lab Clin Med (1994) 0.99
NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J Physiol Cell Physiol (2001) 0.98
Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer (2007) 0.98
Excess heme in sickle erythrocyte inside-out membranes: possible role in thiol oxidation. Blood (1988) 0.98
Nonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation. Blood (1988) 0.97
Improved microvascular network in vitro by human blood outgrowth endothelial cells relative to vessel-derived endothelial cells. Tissue Eng (2005) 0.97
Modulation of erythrocyte-endothelial interactions and the vasocclusive severity of sickling disorders. Blood (1981) 0.96
Identification and functional assessment of endothelial P1H12. J Lab Clin Med (2001) 0.96
Lipid hydroperoxides permit deformation-dependent leak of monovalent cation from erythrocytes. Blood (1991) 0.95
The molecular pathobiology of cell membrane iron: the sickle red cell as a model. Free Radic Biol Med (1998) 0.93
Inhibition of erythrocyte Ca2+-ATPase by activated oxygen through thiol- and lipid-dependent mechanisms. Biochim Biophys Acta (1986) 0.91
Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. Blood (1997) 0.91
Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Ther (2010) 0.91
Characterization of high- and low-metastatic clones derived from a methylcholanthrene-induced murine fibrosarcoma. Cancer Res (1982) 0.88
Comparative oxidation of hemoglobins A and S. Blood (1998) 0.88
Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood (1987) 0.88
Effect of increased maternal hemoglobin oxygen affinity on fetal growth in the rat. Blood (1980) 0.88
Ethane production as a measure of lipid peroxidation after renal ischemia. Am J Physiol (1986) 0.88
Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J Clin Invest (1997) 0.86
Effect of pyruvate on oxidant injury to isolated and cellular DNA. Kidney Int (1994) 0.85
Erythrocyte/endothelial interactions in the pathogenesis of sickle-cell disease: a "real logical" assessment. Blood Cells (1982) 0.85
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood (1995) 0.85
Abnormal erythrocyte calcium homeostasis in oxidant-induced hemolytic disease. Blood (1981) 0.84
Detection, characterization, and bioavailability of membrane-associated iron in the intact sickle red cell. J Clin Invest (1992) 0.84
Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo. Br J Anaesth (2013) 0.83
Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. J Lab Clin Med (1999) 0.83
Erytrocyte adherence to endothelium as a determinant of vasocclusive severity in sickle cell disease. Trans Assoc Am Physicians (1980) 0.83
Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes. Blood (1993) 0.83
Exaggerated cation leak from oxygenated sickle red blood cells during deformation: evidence for a unique leak pathway. Blood (1992) 0.82
Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta (1999) 0.82
Preferential targeting of oxidative base damage to internucleosomal DNA. Carcinogenesis (1996) 0.82
Diphenylamine: an unusual antioxidant. Free Radic Biol Med (1993) 0.82
Catalysis of soluble hemoglobin oxidation by free iron on sickle red cell membranes. Blood (1996) 0.81
Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med (1999) 0.81
Monozygotic twins with sickle cell anemia and discordant clinical courses: clinical and laboratory studies. Hemoglobin (1991) 0.81
The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood (1998) 0.80
Poly (lactic acid)-chitosan-collagen composite nanofibers as substrates for blood outgrowth endothelial cells. Int J Biol Macromol (2013) 0.80
Erythrocyte/endothelial interactions and the vasocclusive severity of sickle cell disease. Prog Clin Biol Res (1981) 0.79
Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation. Thromb Haemost (2001) 0.79
Oxidation of membrane thiols in sickle erythrocytes. Prog Clin Biol Res (1984) 0.79
Phospholipid asymmetry during erythrocyte deformation: maintenance of the unit membrane. Biochim Biophys Acta (1992) 0.78
Hypoxic ventilatory response in subjects with normal and high oxygen affinity hemoglobins. J Clin Invest (1977) 0.78
Extremely high avidity association of Fe(III) with the sickle red cell membrane. Blood (1996) 0.78
Erythrocyte calcium abnormalities in sickle cell disease. Prog Clin Biol Res (1981) 0.78
Desferrioxamine (DFO) conjugated with starch decreases NAD redox potential of intact red blood cells (RBC): evidence for DFO as an extracellular inducer of oxidant stress in RBC. Am J Hematol (2000) 0.78
Pathogenesis of sickle cell disease. Pathobiol Annu (1981) 0.77
Sickle cell disease: beyond the hemoglobin abnormality. Prog Clin Biol Res (1982) 0.77
Denaturing interaction between sickle hemoglobin and phosphatidylserine liposomes. Blood (1994) 0.77
Erythrocyte autoxidation and the membrane abnormalities of sickle red cells. Prog Clin Biol Res (1984) 0.76
Internucleosomal cleavage of DNA is insufficient evidence to conclude that cell death is apoptotic. Blood (1994) 0.76
Hemoglobin oxygen affinity and adaptation to altitude: evidence for pre-adaptation to altitude in humans with left-shifted oxyhemoglobin dissociation curves. Trans Assoc Am Physicians (1978) 0.75
Iron compartments associated with sickle RBC membranes: a mechanism for the targeting of oxidative damage. Prog Clin Biol Res (1989) 0.75
Vesiculation of sickle erythrocytes during thermal stress. Blood (1988) 0.75
Erythrocyte (Ca+2 + Mg+2)-ATPase activity: increased sensitivity to oxidative stress in glucose-6-phosphate dehydrogenase deficiency. Am J Hematol (1985) 0.75
Calmodulin and the red cell membrane. Prog Clin Biol Res (1982) 0.75
Extreme but asymptomatic carboxyhemoglobinemia and chronic lung disease. JAMA (1978) 0.75
Thrombin-stimulated calcium mobilization is inhibited by thrombospondin via CD36. Exp Cell Res (1998) 0.75
Endothelial adhesivity of sickle red blood cells. J Lab Clin Med (1992) 0.75
Erythrocyte antioxidants and membrane vulnerability. J Lab Clin Med (1986) 0.75
Erythrophagocytosis as a determinant of hemolytic rate in sickle disease. Prog Clin Biol Res (1984) 0.75
Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol (1999) 0.75
Deformation of swollen erythrocytes provides a model of sickling-induced leak pathways, including a novel bromide-sensitive component. Blood (1994) 0.75
Utilization of humans with high oxygen affinity hemoglobins in identifying mediators of physiologic responses to hypoxia. Prog Clin Biol Res (1978) 0.75
Influence of antioxidants on arachidonic acid metabolism and platelet function. Biochem Med Metab Biol (1994) 0.75